Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow ...

On Friday, H.C. Wainwright analyst Raghuram Selvaraju increased the price target on Verona Pharma (NASDAQ:VRNA) to $75.00, up from ...

In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his ...

UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after a formulation delivered with an inhaler met its goals in a phase 2 trial.

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on April 3 and set a price target of $330.00. The company’s shares closed yesterday at $235.74.

Scienture (SCNX) announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions, Bonum ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result in shortages and higher prices for generic drugs. By Rebecca Robbins ...